Personalized treatment approach for pancreatic cancer
A Single-centric, Prospective, Open, Interventional Clinical Trial, About Personalized Precision Diagnosis and Treatment of Pancreatic Cancer
This study is testing a personalized treatment for pancreatic cancer by using blood tests to track tumor cells and matching drug therapies to each patient's unique cancer.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 20 Years to 75 Years |
| Sex | All |
| Sponsor | Changhai Hospital Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Shanghai) |
| Trial ID | NCT04373928 on ClinicalTrials.gov |
What this trial studies
This study focuses on the personalized diagnosis and treatment of pancreatic cancer using circulating tumor cells (CTC) and patient-derived xenografts (PDX). By analyzing CTC counts through a non-invasive liquid biopsy method, the study aims to correlate these counts with the progression of pancreatic cancer. The intervention involves using drug treatments guided by Mini-PDX and PDX models to tailor therapy based on individual tumor characteristics. The goal is to enhance the accuracy of diagnosis and improve treatment outcomes for patients with pancreatic cancer.
Who should consider this trial
Good fit: Ideal candidates for this study are patients undergoing radical resection of pancreatic cancer without serious underlying diseases.
Not a fit: Patients with poor preoperative conditions or those who have undergone preoperative chemotherapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more effective and personalized treatment options for patients with pancreatic cancer.
How similar studies have performed: Other studies have shown promise in using CTCs for cancer diagnosis and monitoring, suggesting that this approach may be effective.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Undergoing radical resection of pancreatic cancer; * No serious underlying disease; * No preoperative chemotherapy; * The diagnosis of pancreatic cancer; * No significant heart, lung or renal function; * No HIV or syphilis infection; * All patients should sign the informed consent. Exclusion Criteria: * Preoperative general condition was poor, and it was estimated that the operation and postoperative chemotherapy and targeted therapy could not be tolerated; * Patients with unstable angina pectoris, symptomatic congestive heart failure, severe arrhythmia, cardiac infarction in the past 6 months, and prolonged QT interval (\>450ms). * Patients with other malignancies in the last 5 years. * Patients are not subject to follow-up or other clinical trials.
Where this trial is running
Shanghai
- Changhai Hospital — Shanghai, China (Recruiting)
Study contacts
- Study coordinator: Guo Shiwei, M.D.
- Email: gestwa@163.com
- Phone: 18621500666
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.